Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Clinical Trials in Bunkyō-Ku, Tokyo

A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma